Clinical Trials Browser

Approved for marketing × eribulin × Clear all

NCT01240421 2015-05-22

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Approved for marketing

Breast Neoplasms